scholarly journals Pregnancy-Onset Acute Severe Colitis after in vitro Fertilization Embryo Transfer

2020 ◽  
Vol 14 (3) ◽  
pp. 477-482
Author(s):  
Dora Grgić ◽  
Silvija Čuković Čavka ◽  
Vesna Elveđi Gašparović ◽  
Nikša Turk ◽  
Marko Brinar ◽  
...  

Inflammatory bowel diseases (IBD) usually affect women in their fertile years and, therefore, have implications for their fertility and pregnancy. The presence of IBD during pregnancy has been shown to adversely affect pregnancy outcomes, and increased rates of preterm delivery and of spontaneous abortion have been reported. An onset of acute severe colitis in pregnancy has rarely been seen. We present the case of a 42-year-old woman who conceived after 9 attempts of in vitro fertilization and whose pregnancy was the result of a donated oocyte. Shortly after conception, she was diagnosed with severe active ulcerative colitis, and biologic therapy was introduced in the 28th week of pregnancy. Although therapy for IBD in pregnancy is considered safe for most drugs, this was not very well known in 2015. We also consider our case exceptional because we now have a 5-year follow-up of our patient and her child after having begun biologic therapy during late pregnancy.

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Shital Julania ◽  
Melanie L. Walls ◽  
Roger Hart

In vitro maturation (IVM) of human oocytes is an emerging treatment option for women with polycystic ovary/polycystic ovary syndrome (PCO/PCOS) in addition to the standard in vitro fertilization (IVF) treatment. There has been significant improvements in pregnancy rates with IVM over the last two decades. This article reviews the place of IVM for women with PCO/PCOS, placing an emphasis on the predictors of successful pregnancy, optimization of culture media, IVM protocols, pregnancy rates, and neonatal outcomes following IVM treatment.


2015 ◽  
Vol 13 (9) ◽  
pp. 1641-1646.e3 ◽  
Author(s):  
Sveta Shah Oza ◽  
Vikas Pabby ◽  
Laura E. Dodge ◽  
Vasiliki A. Moragianni ◽  
Michele R. Hacker ◽  
...  

2016 ◽  
Vol 3 (1) ◽  
pp. e199
Author(s):  
Jason J. Pan ◽  
Mora Cannon ◽  
Edward Kane ◽  
Gauree Konijeti

Medicine ◽  
2021 ◽  
Vol 100 (3) ◽  
pp. e24009
Author(s):  
Meiling Yu ◽  
Yanhong Liu ◽  
Dongyun Jia ◽  
Tian Tian ◽  
Qi Xi

Animals ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 1811
Author(s):  
Adrienne E. Crosier ◽  
Julie Lamy ◽  
Priya Bapodra ◽  
Suzi Rapp ◽  
Morgan Maly ◽  
...  

Approximately 30% of the Association of Zoos and Aquariums cheetah population (~350 total animals) is unlikely to breed naturally due to advanced age, health, or behavioral issues. Aging cheetah females (≥9 y old) are unlikely to become pregnant via natural breeding if they are nulliparous. We previously demonstrated that oocytes recovered from aged females were of similar quality compared with those recovered from younger females (2–8 y old). We hypothesize that transfer of 4–8 cell embryos produced by in vitro fertilization with oocytes from old donors could result in pregnancy after transfer into younger recipients. Female cheetahs (n = 3 aging donors and n = 3 young recipients) received 300 IU equine Chorionic Gonadotropin (eCG) and 3000 IU Luteinizing Hormone (LH) while fecal metabolites of estrogens and progestogens were closely monitored. At 28 h post-LH injection, oocytes were aspirated laparoscopically from donors and inseminated in vitro with cryopreserved sperm. After 48 h of in vitro culture, resulting embryos (4–8 cells) were transferred into the oviducts of recipient females. Pregnancy was confirmed in one recipient via ultrasound 32 days after transfer and by radiograph 62 days after transfer. Two cubs were born naturally after 90 days of gestation, representing the first cheetah births resulting from transfer of embryos produced in vitro.


2019 ◽  
Vol 8 (12) ◽  
pp. 2169
Author(s):  
Christine Verdon ◽  
Talat Bessissow ◽  
Peter L. Lakatos

Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%–30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as well as the availability of new treatment options with the development of new biological and small molecules; however, data is limited regarding their use in the context of ASUC. This review aims to discuss the emerging data regarding biologicals and small molecules therapies in the context of ASUC.


2016 ◽  
Vol 61 (8) ◽  
pp. 2381-2388 ◽  
Author(s):  
Sveta Shah Oza ◽  
Vikas Pabby ◽  
Laura E. Dodge ◽  
Michele R. Hacker ◽  
Janis H. Fox ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document